Table 4.
The associations of relative temporal changes in serum PGI, PGII, the PGI/II ratio, gastrin-17 and anti-H. pylori IgG levels with progression of gastric precancerous lesions stratified by baseline serological test results; Zhuanghe Gastric Diseases Screening Program, China
| Abnormal baseline biomarker tests2 (n = 1,612) |
Normal baseline biomarker tests3 (n=363) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Relative change1 | OR4 | 95% CI | p value | OR4 | 95% CI | p value | ||
| Serum PGI | ||||||||
| Decreased ≥50% | 1.00 | N/A | 1.00 | N/A | ||||
| Decreased 20-50% | 1.02 | 0.73 | 1.43 | 0.73 | 0.36 | 1.47 | ||
| Within 20% | 1.34 | 0.97 | 1.86 | 0.85 | 0.46 | 1.55 | ||
| Increased 20-50% | 1.55 | 1.07 | 2.24 | <0.01 | 1.06 | 0.51 | 2.19 | 0.05 |
| Increased ≥50% | 1.58 | 1.09 | 2.30 | 1.61 | 0.86 | 3.03 | ||
| Serum PGII | ||||||||
| Decreased ≥50% | 1.00 | N/A | 1.00 | N/A | ||||
| Decreased 20-50% | 1.50 | 1.13 | 1.99 | 1.48 | 0.53 | 4.12 | ||
| Within 20% | 1.45 | 1.09 | 1.95 | 1.62 | 0.59 | 4.44 | ||
| Increased 20-50% | 1.42 | 1.00 | 2.03 | <0.01 | 1.17 | 0.40 | 3.43 | 0.10 |
| Increased ≥50% | 1.61 | 1.20 | 2.16 | 1.93 | 0.79 | 4.73 | ||
| Serum PGI/II ratio | ||||||||
| Increased ≥50% | 1.00 | N/A | 1.00 | N/A | ||||
| Increased 20-50% | 1.07 | 0.77 | 1.48 | 2.81 | 1.21 | 6.51 | ||
| Within 20% | 1.19 | 0.92 | 1.54 | 1.29 | 0.60 | 2.79 | ||
| Decreased 20-50% | 0.86 | 0.63 | 1.17 | 0.21 | 1.56 | 0.77 | 3.19 | 0.87 |
| Decreased ≥50% | 1.42 | 1.04 | 1.93 | 1.38 | 0.69 | 2.72 | ||
| Serum gastrin-17 | ||||||||
| Decreased ≥100% | 1.00 | N/A | 1.00 | N/A | ||||
| Decreased 20-100% | 1.02 | 0.71 | 1.46 | 0.81 | 0.34 | 1.93 | ||
| Within 20% | 0.77 | 0.54 | 1.09 | 0.92 | 0.46 | 1.85 | ||
| Increased 20-500% | 1.18 | 0.84 | 1.65 | 0.16 | 1.04 | 0.53 | 2.06 | 0.13 |
| Increased ≥500% | 1.19 | 0.81 | 1.75 | 1.51 | 0.73 | 3.09 | ||
| Serum anti-H. pylori IgG | ||||||||
| Decreased ≥50% | 1.00 | N/A | 1.00 | N/A | ||||
| Decreased 20-50% | 1.10 | 0.80 | 1.51 | 2.48 | 1.04 | 5.91 | ||
| Within 20% | 1.46 | 1.09 | 1.97 | 3.42 | 1.49 | 7.84 | ||
| Increased 20-50% | 1.49 | 1.01 | 2.19 | <0.01 | 3.33 | 1.25 | 8.83 | 0.02 |
| Increased ≥50% | 1.87 | 1.38 | 2.52 | 2.60 | 1.25 | 5.40 | ||
1
Defined as: (follow-up - baseline)/baseline × 100%.
2
PGII ≥8.3 ng/mL or anti-H. pylori IgG ≥ 24.0 EIU.
3
PGII <8.3 ng/mL and anti-H. pylori IgG <24.0 EIU.
4
Estimated using generalized estimating equations (GEE) for correlated binary outcomes.
Abbreviations: CI: confidence interval; H. pylori: Helicobacter pylori; OR: odds ratio; PG: pepsinogen.